Sodium glucose cotransporters inhibitors in type 1 diabetes

Sergio Dellepiane; Moufida Ben Nasr; Emma Assi; Vera Usuelli; Teresa Letizia; Francesca D'Addio; Gian Vincenzo Zuccotti; Paolo Fiorina

doi:10.1016/j.phrs.2018.04.018

Sodium glucose cotransporters inhibitors in type 1 diabetes

Pharmacol Res. 2018 Jul:133:1-8. doi: 10.1016/j.phrs.2018.04.018. Epub 2018 Apr 22.

Authors

Sergio Dellepiane¹, Moufida Ben Nasr², Emma Assi², Vera Usuelli², Teresa Letizia³, Francesca D'Addio³, Gian Vincenzo Zuccotti⁴, Paolo Fiorina⁵

Affiliations

¹ Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
² Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; International Center for T1D, Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science L. Sacco, University of Milan, Milan, Italy.
³ International Center for T1D, Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science L. Sacco, University of Milan, Milan, Italy; Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
⁴ Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science L. Sacco, University of Milan, Italy; Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy.
⁵ Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; International Center for T1D, Pediatric Clinical Research Center Fondazione Romeo ed Enrica Invernizzi, Department of Biomedical and Clinical Science L. Sacco, University of Milan, Milan, Italy; Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy. Electronic address: [email protected].

PMID: 29689314
DOI: 10.1016/j.phrs.2018.04.018

Abstract

Sodium glucose cotransporter inhibitors (SGLTi) are oral hypoglycemic drugs that reduce renal glucose re-uptake and induce glycosuria. SGLTi have been successfully tested in large randomized clinical trials for type 2 diabetes, and several molecules have been approved in this setting by the international pharmaceutical agencies. Additionally, recent evidence has shown that SGLTi may be useful also in type 1 diabetes (T1D). Indeed, these drugs can be used as an ancillary to insulin to improve glycemic control and reduce insulin dosage, and such regimens have been associated with a lower rate of hypoglycemic episodes. The pharmacological effects of SGLTi therapy are described herein, and we also discuss the future use of SGLTi in T1D.

Keywords: Diabetic kidney disease; Gliflozin; SGLT1; SGLT2; Type 1 diabetes.

Publication types

Review

MeSH terms

Animals
Diabetes Mellitus, Type 1 / drug therapy*
Diabetes Mellitus, Type 1 / metabolism
Humans
Hypoglycemic Agents / therapeutic use*
Sodium-Glucose Transport Proteins / antagonists & inhibitors*
Sodium-Glucose Transport Proteins / metabolism

Substances

Hypoglycemic Agents
Sodium-Glucose Transport Proteins